A number of biosimilars have been approved in recent years, offering additional treatment options for patients with IBD. Given the novelty of biosimilars in the U.S., it’s not surprising that clinicians have questions.

Find this FREE CME Activity here: www.cmecorner.com/biosimilars

In this expert panel discussion, faculty will define biosimilars, examine how they’re studied and regulated, and assess their current and potential role in IBD management, including how they might contribute to value-based care.

Target Audience

Gastroenterologists, primary care physicians, NPs, PAs, and other healthcare providers who care for patients with IBD.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Review how biosimilars are similar to and different from their originator biologic.
  2. Discuss the biosimilar regulatory review process and similarities in safety and efficacy between biosimilars and originator biologics.
  3. Identify biosimilars approved for the treatment of patients with IBD.
  4. Describe value-based care and how it differs from fee-for-service care models.
  5. Discuss how the use of biosimilars will provide value-based care by improving patients’ health outcomes and quality of care.

CCME Reviewer:

Thomas A. Ullman, MD
Professor of Medicine
Chief, Division of Gastroenterology
Albert Einstein College of Medicine/
Montefiore Medical Center
Bronx, NY


Russell D. Cohen, MD, FACG, AGAF
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
The University of Chicago Medicine
Professor of Medicine
Pritzker School of Medicine
Chicago, IL

Gil Y. Melmed, MD, MS
Co-Director, Clinical Inflammatory Bowel Disease
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Sushila Dalal, MD
Inflammatory Bowel Disease Center
The University of Chicago Medicine
Assistant Professor of Medicine
Pritzker School of Medicine
Chicago, IL

Continuing Education Credit


ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Albert Einstein College of Medicine, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant from Pfizer Inc